International Journal of Antimicrobial Agents
Volume 35, Issue 5 , Pages 431-438 , May 2010

Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic/pharmacodynamic indices

  • April Barbour

      Affiliations

    • GlaxoSmithKline, King of Prussia, PA, USA
    • ,
  • Francesco Scaglione

      Affiliations

    • Department of Pharmacology, Medical School, University of Milan, Milan, Italy
    • ,
  • Hartmut Derendorf

      Affiliations

    • Department of Pharmaceutics, College of Pharmacy, University of Florida, 1600 SW Archer Road, Room P3-20, P.O. Box 100494, Gainesville, FL 32610, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 352 273 7856; fax: +1 352 392 3249.

References 

  1. Eagle H, Fleischman R, Levy M. ‘Continuous’ vs. ‘discontinuous’ therapy with penicillin; the effect of the interval between injections on therapeutic efficacy. N Engl J Med. 1953;248:481–488
  2. Eagle H, Fleischman R, Musselman AD. The bactericidal action of penicillin in vivo: the participation of the host, and the slow recovery of the surviving organisms. Ann Intern Med. 1950;33:544–571
  3. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1–10[quiz 11–2]
  4. Andes D, Craig WA. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother. 2007;51:1633–1642
  5. Andes D, van Ogtrop ML, Peng J, Craig WA. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother. 2002;46:3484–3489
  6. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, et al. Pharmacokinetics–pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis. 2007;44:79–86
  7. Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis Suppl. 1990;74:63–70
  8. Lacy MK, Nicolau DP, Nightingale CH, Quintiliani R. The pharmacodynamics of aminoglycosides. Clin Infect Dis. 1998;27:23–27
  9. Nielsen EI, Viberg A, Lowdin E, Cars O, Karlsson MO, Sandstrom M. Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time–kill curve experiments. Antimicrob Agents Chemother. 2007;51:128–136
  10. Bundtzen RW, Gerber AU, Cohn DL, Craig WA. Postantibiotic suppression of bacterial growth. Rev Infect Dis. 1981;3:28–37
  11. Craig WA. Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man. J Antimicrob Chemother. 1993;31(Suppl. D):149–158
  12. Vogelman B, Craig WA. Kinetics of antimicrobial activity. J Pediatr. 1986;108:835–840
  13. Nix DE, Matthias KR, Ferguson EC. Effect of ertapenem protein binding on killing of bacteria. Antimicrob Agents Chemother. 2004;48:3419–3424
  14. Schmidt S, Rock K, Sahre M, Burkhardt O, Brunner M, Lobmeyer MT, et al. Effect of protein binding on the pharmacological activity of highly bound antibiotics. Antimicrob Agents Chemother. 2008;52:3994–4000
  15. Zeitlinger M, Sauermann R, Fille M, Hausdorfer J, Leitner I, Muller M. Plasma protein binding of fluoroquinolones affects antimicrobial activity. J Antimicrob Chemother. 2008;61:561–567
  16. Burgess DS, Frei CR. Comparison of β-lactam regimens for the treatment of Gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics. J Antimicrob Chemother. 2005;56:893–898
  17. Turnidge J. Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin North Am. 2003;17:503–528v
  18. Stalker DJ, Jungbluth GL, Hopkins NK, Batts DH. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemother. 2003;51:1239–1246
  19. Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs. 1999;58(Suppl. 2):29–36
  20. Zhanel GG, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Embil J, et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs. 2004;64:63–88
  21. Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother. 2005;49:220–229
  22. Conte JE, Golden JA, Kelly MG, Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents. 2005;25:523–529
  23. Jain R, Danziger LH. The macrolide antibiotics: a pharmacokinetic and pharmacodynamic overview. Curr Pharm Des. 2004;10:3045–3053
  24. Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, Barriere S. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother. 2005;49:195–201
  25. Leighton A, Gottlieb AB, Dorr MB, Jabes D, Mosconi G, VanSaders C, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother. 2004;48:940–945
  26. Matzke GR, Zhanel GG, Guay DR. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet. 1986;11:257–282
  27. Bustamante CI, Drusano GL, Tatem BA, Standiford HC. Postantibiotic effect of imipenem on Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1984;26:678–682
  28. Parker RF, Luse S. The action of penicillin on Staphylococcus: further observations on the effect of a short exposure. J Bacteriol. 1948;56:75–81
  29. Vogelman B, Gudmundsson S, Turnidge J, Leggett J, Craig WA. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis. 1988;157:287–298
  30. Craig WA, Andes DR. In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models. Antimicrob Agents Chemother. 2008;52:3492–3496
  31. Majumdar AK, Musson DG, Birk KL, Kitchen CJ, Holland S, McCrea J, et al. Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob Agents Chemother. 2002;46:3506–3511
  32. AstraZeneca. Merrem® I.V. prescribing information. AstraZeneca; 2007. http://www1.astrazeneca-us.com/pi/MerremIV.pdf [accessed 23 December 2008].
  33. Bhavnani S. Which PK/PD index for which drug? In: International Society of Antimicrobial Pharmacology William A. Craig Symposium; 29 October 2008, Madison, WI.
  34. Karjagin J, Lefeuvre S, Oselin K, Kipper K, Marchand S, Tikkerberi A, et al. Pharmacokinetics of meropenem determined by microdialysis in the peritoneal fluid of patients with severe peritonitis associated with septic shock. Clin Pharmacol Ther. 2008;83:452–459
  35. Legat FJ, Krause R, Zenahlik P, Hoffmann C, Scholz S, Salmhofer W, et al. Penetration of piperacillin and tazobactam into inflamed soft tissue of patients with diabetic foot infection. Antimicrob Agents Chemother. 2005;49:4368–4371
  36. Tomaselli F, Maier A, Matzi V, Smolle-Juttner FM, Dittrich P. Penetration of meropenem into pneumonic human lung tissue as measured by in vivo microdialysis. Antimicrob Agents Chemother. 2004;48:2228–2232
  37. Edson RS, Terrell CL. The aminoglycosides. Mayo Clin Proc. 1991;66:1158–1164
  38. Begg EJ, Peddie BA, Chambers ST, Boswell DR. Comparison of gentamicin dosing regimens using an in-vitro model. J Antimicrob Chemother. 1992;29:427–433
  39. Kashuba AD, Nafziger AN, Drusano GL, Bertino JS. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by Gram-negative bacteria. Antimicrob Agents Chemother. 1999;43:623–629
  40. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis. 1988;158:831–847
  41. Blaser J, Stone BB, Groner MC, Zinner SH. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother. 1987;31:1054–1060
  42. Bryan LE, Van Den Elzen HM. Effects of membrane-energy mutations and cations on streptomycin and gentamicin accumulation by bacteria: a model for entry of streptomycin and gentamicin in susceptible and resistant bacteria. Antimicrob Agents Chemother. 1977;12:163–177
  43. Daikos GL, Lolans VT, Jackson GG. First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. Antimicrob Agents Chemother. 1991;35:117–123
  44. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39:650–655
  45. Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, Ioannidis JP. Extended-interval aminoglycoside administration for children: a meta-analysis. Pediatrics. 2004;114:e111–e118
  46. Lorentzen H, Kallehave F, Kolmos HJ, Knigge U, Bulow J, Gottrup F. Gentamicin concentrations in human subcutaneous tissue. Antimicrob Agents Chemother. 1996;40:1785–1789
  47. Myers DR, DeFehr J, Bennet WM, Porter GA, Olsen GD. Gentamicin binding to serum and plasma proteins. Clin Pharmacol Ther. 1978;23:356–360
  48. Fukuda H, Hiramatsu K. Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother. 1999;43:410–412
  49. Gootz TD, Zaniewski R, Haskell S, Schmieder B, Tankovic J, Girard D, et al. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrob Agents Chemother. 1996;40:2691–2697
  50. Suerbaum S, Leying H, Kroll HP, Gmeiner J, Opferkuch W. Influence of β-lactam antibiotics and ciprofloxacin on cell envelope of Escherichia coli. Antimicrob Agents Chemother. 1987;31:1106–1110
  51. Forrest A, Chodosh S, Amantea MA, Collins DA, Schentag JJ. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother. 1997;40(Suppl. A):45–57
  52. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993;37:1073–1081
  53. Drusano GL, Preston SL, Fowler C, Corrado M, Weisinger B, Kahn J. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis. 2004;189:1590–1597
  54. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA. 1998;279:125–129
  55. Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother. 2001;45:2793–2797
  56. Drusano GL, Johnson DE, Rosen M, Standiford HC. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother. 1993;37:483–490
  57. Zeitlinger MA, Traunmuller F, Abrahim A, Muller MR, Erdogan Z, Muller M, et al. A pilot study testing whether concentrations of levofloxacin in interstitial space fluid of soft tissues may serve as a surrogate for predicting its pharmacokinetics in lung. Int J Antimicrob Agents. 2007;29:44–50
  58. Schuck EL, Grant M, Derendorf H. Effect of simulated microgravity on the disposition and tissue penetration of ciprofloxacin in healthy volunteers. J Clin Pharmacol. 2005;45:822–831
  59. Islinger F, Bouw R, Stahl M, Lackner E, Zeleny P, Brunner M, et al. Concentrations of gemifloxacin at the target site in healthy volunteers after a single oral dose. Antimicrob Agents Chemother. 2004;48:4246–4249
  60. Bozdogan B, Esel D, Whitener C, Browne FA, Appelbaum PC. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother. 2003;52:864–868
  61. Cercenado E, Garcia-Garrote F, Bouza E. In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates. J Antimicrob Chemother. 2001;47:77–81
  62. Hoellman DB, Lin G, Ednie LM, Rattan A, Jacobs MR, Appelbaum PC. Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents. Antimicrob Agents Chemother. 2003;47:1148–1150
  63. Zhou CC, Swaney SM, Shinabarger DL, Stockman BJ. 1H nuclear magnetic resonance study of oxazolidinone binding to bacterial ribosomes. Antimicrob Agents Chemother. 2002;46:625–629
  64. Bobkova EV, Yan YP, Jordan DB, Kurilla MG, Pompliano DL. Catalytic properties of mutant 23 S ribosomes resistant to oxazolidinones. J Biol Chem. 2003;278:9802–9807
  65. Zurenko GE, Yagi BH, Schaadt RD, Allison JW, Kilburn JO, Glickman SE, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother. 1996;40:839–845
  66. Rybak MJ, Cappelletty DM, Moldovan T, Aeschlimann JR, Kaatz GW. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother. 1998;42:721–724
  67. Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet. 2003;42:1411–1423
  68. Dehghanyar P, Burger C, Zeitlinger M, Islinger F, Kovar F, Muller M, et al. Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses. Antimicrob Agents Chemother. 2005;49:2367–2371
  69. MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother. 2003;51(Suppl. 2):ii17–ii25
  70. Noviello S, Ianniello F, Leone S, Fiore M, Esposito S. In vitro activity of tigecycline: MICs, MBCs, time–kill curves and post-antibiotic effect. J Chemother. 2008;20:577–580
  71. van Ogtrop ML, Andes D, Stamstad TJ, Conklin B, Weiss WJ, Craig WA, et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various Gram-positive and Gram-negative bacteria. Antimicrob Agents Chemother. 2000;44:943–949
  72. Petersen PJ, Jones CH, Bradford PA. In vitro antibacterial activities of tigecycline and comparative agents by time–kill kinetic studies in fresh Mueller–Hinton broth. Diagn Microbiol Infect Dis. 2007;59:347–349
  73. Cunha BA, Domenico P, Cunha CB. Pharmacodynamics of doxycycline. Clin Microbiol Infect. 2000;6:270–273
  74. Meagher AK, Passarell JA, Cirincione BB, Van Wart SA, Liolios K, Babinchak T, et al. Exposure–response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother. 2007;51:1939–1945
  75. Passarell JA, Meagher AK, Liolios K, Cirincione BB, Van Wart SA, Babinchak T, et al. Exposure–response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother. 2008;52:204–210
  76. Odenholt I, Lowdin E, Cars O. The effects of protein binding on the pharmacodynamics of tigecycline against Staphylococcus aureus and Escherichia coli. In: 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annual Meeting, 25–28 October 2008, Washington, DC. Washington, DC: ASM Press; 2008;
  77. Lovmar M, Tenson T, Ehrenberg M. Kinetics of macrolide action: the josamycin and erythromycin cases. J Biol Chem. 2004;279:53506–53515
  78. Fernandes PB, Bailer R, Swanson R, Hanson CW, McDonald E, Ramer N, et al. In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. Antimicrob Agents Chemother. 1986;30:865–873
  79. Retsema J, Girard A, Schelkly W, Manousos M, Anderson M, Bright G, et al. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against Gram-negative organisms. Antimicrob Agents Chemother. 1987;31:1939–1947
  80. Andes D, Anon J, Jacobs MR, Craig WA. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. Clin Lab Med. 2004;24:477–502
  81. Odenholt-Tornqvist I, Lowdin E, Cars O. Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens. Antimicrob Agents Chemother. 1995;39:221–226
  82. Ramadan MA, Tawfik AF, Shibl AM, Gemmell CG. Post-antibiotic effect of azithromycin and erythromycin on streptococcal susceptibility to phagocytosis. J Med Microbiol. 1995;42:362–366
  83. Van Bambeke F, Tulkens PM. Macrolides: pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents. 2001;18(Suppl. 1):S17–S23
  84. den Hollander JG, Knudsen JD, Mouton JW, Fuursted K, Frimodt-Moller N, Verbrugh HA, et al. Comparison of pharmacodynamics of azithromycin and erythromycin in vitro and in vivo. Antimicrob Agents Chemother. 1998;42:377–382
  85. Nightingale CH. Pharmacokinetics and pharmacodynamics of newer macrolides. Pediatr Infect Dis J. 1997;16:438–443
  86. Novelli A, Fallani S, Cassetta MI, Arrigucci S, Mazzei T. In vivo pharmacodynamic evaluation of clarithromycin in comparison to erythromycin. J Chemother. 2002;14:584–590
  87. Shi J, Montay G, Bhargava VO. Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin Pharmacokinet. 2005;44:915–934
  88. Lodise TP, Preston S, Bhargava V, Bryskier A, Nusrat R, Chapel S, et al. Pharmacodynamics of an 800-mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens. Diagn Microbiol Infect Dis. 2005;52:45–52
  89. Perret C, Lenfant B, Weinling E, Wessels DH, Scholtz HE, Montay G, et al. Pharmacokinetics and absolute oral bioavailability of an 800-mg oral dose of telithromycin in healthy young and elderly volunteers. Chemotherapy. 2002;48:217–223
  90. Gattringer R, Urbauer E, Traunmuller F, Zeitlinger M, Dehghanyar P, Zeleny P, et al. Pharmacokinetics of telithromycin in plasma and soft tissues after single-dose administration to healthy volunteers. Antimicrob Agents Chemother. 2004;48:4650–4653
  91. Bosnar M, Kelneric Z, Munic V, Erakovic V, Parnham MJ. Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. Antimicrob Agents Chemother. 2005;49:2372–2377
  92. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother. 1989;33:277–282
  93. Nguyen M, Chung EP. Telithromycin: the first ketolide antimicrobial. Clin Ther. 2005;27:1144–1163
  94. Muller-Serieys C, Andrews J, Vacheron F, Cantalloube C. Tissue kinetics of telithromycin, the first ketolide antibacterial. J Antimicrob Chemother. 2004;53:149–157
  95. Schentag JJ, Ballow CH. Tissue-directed pharmacokinetics. Am J Med. 1991;91:5S–11S
  96. Amsden GW. Advanced-generation macrolides: tissue-directed antibiotics. Int J Antimicrob Agents. 2001;18(Suppl. 1):S11–S15
  97. Lucini V, Grosso S, Pannacci M, Scaglione F. Azithromycin kinetics in infected tissue evaluated by microdialysis. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 27–30 September 2006, San Francisco, CA. Washington, DC: ASM Press; 2007;[Abstract A-335]
  98. Freeman CD, Nightingale CH, Nicolau DP, Belliveau PP, Banevicius MA, Quintiliani R. Intracellular and extracellular penetration of azithromycin into inflammatory and noninflammatory blister fluid. Antimicrob Agents Chemother. 1994;38:2449–2451
  99. Reynolds PE. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis. 1989;8:943–950
  100. Larsson AJ, Walker KJ, Raddatz JK, Rotschafer JC. The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions. J Antimicrob Chemother. 1996;38:589–597
  101. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006;42(Suppl. 1):S35–S39
  102. Fasola E, Spangler SK, Ednie LM, Jacobs MR, Bajaksouzian S, Appelbaum PC. Comparative activities of LY 333328, a new glycopeptide, against penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother. 1996;40:2661–2663
  103. Biavasco F, Vignaroli C, Lupidi R, Manso E, Facinelli B, Varaldo PE. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide. Antimicrob Agents Chemother. 1997;41:2165–2172
  104. Lowdin E, Odenholt I, Cars O. In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother. 1998;42:2739–2744
  105. Steiert M, Schmitz FJ. Dalbavancin (Biosearch Italia/Versicor). Curr Opin Investig Drugs. 2002;3:229–233
  106. Ebert S. In vivo cidal activity and pharmacokinetic parameters for vancomycin against methicillin-susceptible and -resistant S. aureus. In: 27th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 4–7 October 1987, New York, NY. Washington, DC: ASM; 1987;
  107. Knudsen JD, Fuursted K, Raber S, Espersen F, Frimodt-Moller N. Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection. Antimicrob Agents Chemother. 2000;44:1247–1254
  108. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43:925–942
  109. Ackerman BH, Taylor EH, Olsen KM, Abdel-Malak W, Pappas AA. Vancomycin serum protein binding determination by ultrafiltration. Drug Intell Clin Pharm. 1988;22:300–303
  110. Sun H, Maderazo EG, Krusell AR. Serum protein-binding characteristics of vancomycin. Antimicrob Agents Chemother. 1993;37:1132–1136
  111. Skhirtladze K, Hutschala D, Fleck T, Thalhammer F, Ehrlich M, Vukovich T, et al. Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob Agents Chemother. 2006;50:1372–1375
  112. Bhavnani SM, Passarell JA, Owen JS, Loutit JS, Porter SB, Ambrose PG. Pharmacokinetic–pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2006;50:994–1000
  113. Boylan CJ, Campanale K, Iversen PW, Phillips DL, Zeckel ML, Parr TR. Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother. 2003;47:1700–1706
  114. Mouton JW, Theuretzbacher U, Craig WA, Tulkens PM, Derendorf H, Cars O. Tissue concentrations: do we ever learn?. J Antimicrob Chemother. 2008;61:235–237
  115. Theuretzbacher U. Tissue penetration of antibacterial agents: how should this be incorporated into pharmacodynamic analyses?. Curr Opin Pharmacol. 2007;7:498–504

PII: S0924-8579(10)00068-3

doi: 10.1016/j.ijantimicag.2010.01.023

International Journal of Antimicrobial Agents
Volume 35, Issue 5 , Pages 431-438 , May 2010

Article Tools

* Image Usage & Resolution